Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Market Report, "Menactra (Meningococcal Vaccines) - Forecast and Market Analysis to 2022", published


Print article Print article
2013-12-22 01:32:52 - New Pharmaceuticals research report from GlobalData is now available from Fast Market Research

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

Menactra (Meningococcal Groups A, C, Y, W-135 polysaccharide diphtheria toxoid conjugate vaccine) is the brand name for Sanofi's tetravalent conjugate vaccine sold in the US and Australia to protect children, adolescents, and adults against four serogroups of N. meningitidis that cause invasive meningococcal disease. In 2005, Menactra became the first conjugate vaccine to be approved in the US for those 11 to 55 years of age. Approval was expanded to those from two to 55 years of age in the US

in 2007, and to those as young as nine months of age in 2011, and it was also licensed for use in Australia in 2011.

Full Report Details at
- www.fastmr.com/prod/719816_menactra_meningococcal_vaccines_forec ..

Scope

* Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Menactra including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Menactra for the top nine countries from 2012 to 2022.
* Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Menactra performance
* Obtain sales forecast for Menactra from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

Report Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis
4 Disease Management
4.1 Meningococcal Immunization Policy
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Menactra
6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.4 Forecast
7 Appendix
7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
7.4.1 Vaccine Coverage
7.4.2 Vaccine Approval vs. Routine Schedule Inclusion
7.4.3 Vaccines Included
7.4.4 Key Launch Dates
7.4.5 General Pricing Assumptions
7.4.6 Individual Vaccine Assumptions
7.5 Physicians and Specialists Included in this Study
7.6 About the Authors
7.6.1 Authors
7.6.2 Reviewers
7.6.3 Global Head of Healthcare
7.7 About GlobalData
7.8 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Symptoms of Meningococcal Disease
Table 2: Meningococcal Immunization Recommendation Agencies by Country
Table 3: Recommended Routine Coverage and Most Administered Meningococcal Vaccines by Country in the Global Markets, 2012
Table 4: Leading Vaccines for Meningococcal Disease, 2012
Table 5: Product Profile - Menactra
Table 6: Menactra SWOT Analysis, 2012
Table 7: Global Sales Forecasts ($m) for Menactra, 2012-2022
Table 8: Key Launch Dates
Table 9: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

1.2 List of Figures
Figure 1: Membrane Structure of N. meningitidis

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser